References
- Simons FE, Bonini S, Cohen S et al. Ancestors of Allergy. Global Medical Communications Ltd., NY, USA (1994).
- Noon L. Prophylactic inoculation against hay fever. Lancet 1572–1573 (1911).
- Freeman J. Further observations of the treatment of hay fever by hypodermic inoculations of pollen vaccine. Lancet 814–817 (1911).
- Freeman J. ‘Rush inoculation’, with special reference to hay fever treatment. Lancet 744–747 (1930).
- Abramson MJ, Puy RM, Weiner JM. Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials. Am. J. Respir. Crit. Care Med. 151, 969–974 (1995).
- Ross RN, Nelson HS, Finegold I. Effectiveness of specific immunotherapy in the treatment of asthma: a meta-analysis of prospective, randomized, double-blind, placebo-controlled studies. Clin. Ther.22, 329–341 (2000).
- Ross RN, Nelson HS, Finegold I. Effectiveness of specific immunotherapy in the treatment of allergic rhinitis: an analysis of randomized, prospective, single- or double-blind, placebo-controlled studies. Clin. Ther.22, 342–350 (2000).
- Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma. Cochrane Database Syst. Rev. CD001186 4, (2003).
- Lowenstein H. Allergen Standardization. The Proceedings of the XII International Congress of Allergology and Clinical Immunoloy. Mosby Company, MO, USA 299–303 (1986).
- Lockey R, Slater J, Esch E. Preparation of standardization of allergen extracts. In: Allergy Principles and Practice, sixth edition. Adkinson F, Franklin MD (Eds), Mosby Company, MO, USA 573–584 (2003).
- Esch R. Manufacturing and standardizing fungal allergen products. J. Allergy Clin. Immunol.113, 210–215 (2004).
- Vailes L, Sridhara S, Cromwell O et al. Quantitation of the major fungal allergens, Alt a 1 and Asp f 1, in commercial allergenic products. J. Allergy Clin. Immunol. 107(4), 641–646 (2001).
- Bousquet J, Lockey RF, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases, WHO Position Paper. Allergy 53(Suppl. 44), 1–42 (1998).
- Slater J, Pastor R. The determination of equivalent doses of standardized allergen vaccines J. Allergy Clin. Immunol.105, 468–474 (2000).
- The use of standardized allergen extracts. Position statement American Academy of Allergy, Asthma and Immunology. J. Allergy Clin. Immunol.99, 583–586 (1997).
- Dreborg S, Frew A. Allergen standardization and skin tests EAACI Position paper. 48(Suppl. 14), 49–82 (1993).
- Dreborg S, Einarsson R. The major allergen content of allergenic preparations reflect their biological activity. Allergy 47, 18–23 (1992).
- Lombardero M, Quirce S, Duffort O et al. Monoclonal antibodies against Olea europaea major allergen: allergenic activity of affinity-purified allergen and depleted extract and development of a radioimmunoassay for the quantitation of the allergen. J. Allergy Clin. Immunol. 89, 884–894 (1992).
- Boluda L, Casanovas M, Prieto JL et al. Determinations of Par j 1 by a competitive enzyme immunoassay using human specific IgE and IgG. Validation by skin prick testing. J. Investig. Allergol. Clin. Immunol. 8, 207–213 (1998).
- Turkeltaub PC. Allergenic extracts. II. In vivo standardization. In: Allergy: Principles and Practice, third edition. Middleton E Jr (Ed.), Mosby Company, MO, USA 388–401 (1988).
- Cabanas R, Lopez-Serrano MC, Carreira J et al. Importance of albumin in cross-reactivity among cat, dog and horse allergens. J. Investig. Allergol. Clin. Immunol. 10, 71–77 (2000).
- Rostrum NH. The use of standardized extracts in allergen immunotherapy J. Allergy Clin. Immunol.106, 41–45 (2000).
- Van Ree R. The create project: EU support for the improvement of allergen standardization in Europe. Allergy 59, 571–574 (2004).
- Larenas D. Personal communication: Presentation at 2005 AAAAI Immunotherapy and Allergy Diagnostics Committee meeting.
- Chapman M, Smith A, Valles L et al. Recombinant allergens for diagnosis and therapy of allergic disease J. Allergy Clin. Immunol.106, 409–418 (2000).
- Nopp A, Hallden G, Lundahl J et al. Comparison of inflammatory responses to genetically engineered hypoallergenic derivatives of the major birch pollen allergen bet v 1 and to recombinant bet v 1 wild type in skin chamber fluids collected from birch pollen-allergic patients. J. Allergy Clin. Immunol.106, 101–109 (2000).
- Bohle B, Breitwieser A, Zwolfer B et al. A novel approach to specific allergy treatment: the recombinant fusion protein of a bacterial cell surface (S-layer) protein and the major birch pollen allergen Bet v 1 (rSbsC-Bet v 1) combines reduced allergenicity with immunomodulating capacity. J. Immunol. 172, 6642–6648 (2004).
- Batard T, Didierlaurent A, Chabre H et al. Characterization of wild type recombinant Bet v 1a as a candidate vaccine against birch pollen allergy. Int. Arch. Allergy Immunol.136, 239–249 (2005).
- Aden E, Weber B, Bossert J et al. Standardization of Alternaria alternata: extraction and quantification of Alt a 1 by using an mab-based 2-site binding assay solution. J. Allergy Clin. Immunol.103, 128–135 (1999).
- Bush RK, Sanchez H, Geisler D. Molecular cloning of a major Alternaria alternata allergen, rAlt a 2. J. Allergy Clin. Immunol. 104, 665–671 (1999).
- Juan A, Asturias J, Ibarrola I et al. Diagnosis of Alternaria alternata sensitization with natural and recombinant Alt a 1 allergens J. Allergy Clin. Immunol.115, 1210–1217 (2005).
- Bousquet J, Ansotegui IJ, van Ree R et al. European Union meets the challenge of the growing importance of allergy and asthma in Europe. Allergy 59, 1–4 (2004).
- Valles L, Tsay, Ferreira F. Successful standardization of purified natural and recombinant mite allergens as part of European Union (EU) CREATE project. AAAAI 2004 annual meeting (2004) (Abstract 446).
- Muller UR, Akdis CA, Fricker M et al. Successful immunotherapy with T cell epitope peptides of bee venom phospholipase A2 induces T cell anergy in bee sting allergic patients, J. Allergy Clin. Immunol.101, 747–754 (1998).
- Oldfield WL, Larche M, Kay AB. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomized controlled trial. Lancet 360, 47–53 (2002).
- Akdis CA, Kussebi F, Pulendran B et al. Inhibition of T helper 2-type responses, IgE production and eosinophilia by synthetic lipopeptides. Eur. J. Immunol. 33, 2717–2726 (2003).
- Simons E, Shikishima Y, Van Nest G et al. Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA J. Allergy Clin. Immunol.113, 1144–1151 (2004).
- Tulic MK, Fiset PO, Christodoulopoulos P et al. Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response. J. Allergy Clin. Immunol.113, 235–241 (2004).
- Alvarez-Cuesta E, Cuesta-Herranz J, Puyana-Ruiz J et al. Monoclonal antibody-standardized cat extract immunotherapy: risk benefit effects from a double-blind placebo study. J. Allergy Clin. Immunol.93, 556–566 (1994).
- Hedlin G, Graff-Lonnevig V, Heilborn H. Immunotherapy with cat- and dog-dander extracts. V. Effects of 3 years of treatment. J. Allergy Clin. Immunol.87, 955–964 (1991).
- Van Metre TE Jr, Marsh DG, Adkinson NF Jr et al. Immunotherapy for cat asthma. J. Allergy Clin. Immunol.82, 1055–1068 (1988).
- Ewbank P, Murray J, Sanders K, Curran-Everett D, Dreskin S, Nelson H. A double-blind placebo-controlled immunotherapy dose-response study with standardized cat extract. J. Allergy Clin. Immunol.111, 155–161 (2003).
- Nanda A, O’Connor M, Anand M et al. Dose-dependence and time course of the immunologic response to administration of standardized cat allergen extract. J. Allergy Clin. Immunol.114, 1339–1344 (2004).
- Dolz I, Martinez-Cocera C, Bartolome JM, Cimarra M. A double-blind, placebo-controlled study of immunotherapy with grass-pollen extract Alutard SQ during a 3-year period with initial rush immunotherapy. Allergy 51, 489–500 (1996).
- Varney VA, Gaga M, Frew AJ et al. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by anti-allergic drugs. Br. Med. J. 302(6771), 265–269 (1991).
- Walker S, Pajno G, Lima GT et al. Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial. J. Allergy Clin. Immunol.107, 87–93 (2001).
- Creticos PS, Marsh DG, Proud D et al. Responses to ragweed-pollen nasal challenge before and after immunotherapy. J. Allergy Clin. Immunol.84, 197–205 (1989).
- Van Metre T, Adkinson F, Amodio F et al. A comparative study of the effectiveness of the Rinkel method in the current standard method of immunotherapy for ragweed pollen hay fever. J. Allergy Clin. Immunol. 66, 500–513 (1980).
- Olsen O, Larsen K, Jacobsen L, Svendsen U. A 1-year, placebo-controlled, double-blind house-dust-mite immunotherapy study in asthmatic adults. Allergy 52, 853–859 (1997).
- Haugaard L, Dahl R, Jacobsen LA. Controlled dose-response study of immunotherapy with standardized, partially purified extract of house dust mite: clinical efficacy and side effects. J. Allergy Clin. Immunol.91, 709–722 (1993).
- Certificate of Analysis for Allergenic Extract: Std. Bermuda grass. Alk-Abello, Inc. Round Rock, TX, USA.
Website
- US Department of Health and Human Services, Food and Drug Administration Center for Biologics Evaluation and Research. Guidance for reviewers. Potency limits for standardized dust mite and grass allergen vaccines: a revised protocol, 2000. www.fda.gov/cber/gdlns/mitegrasvac.htm (Accessed October 2005)